Devices/Diagnostics
Sequella developed several technologies to fill gaps in TB diagnosis and therapy that will assist the company in developing new TB drugs and assure that any new TB drugs commercialized by Sequella will be used correctly. These technologies were, for the most part, developed entirely by grant support (*). We are actively looking for corporate partners for non-core assets that are not yet licensed for commercial development:
|
Point-of-Care (POC) Human TB Diagnostic A Skin Test for Active TB that uses M. tuberculosis MPT64 protein to induce a reversible skin reaction only in patients with infectious TB. The Patch is currently in proof-of-principle clinical assessment in the Philippines. For more information, please see our TB Patch Backgrounder. |
|
|
*Wristwatch Compliance Monitor A device to measure medication ingestion. Prototype is in clinical assessment at Wills Eye Institute in Philadelphia, PA. Sequella is actively looking for a corporate partner to commercialize the device to monitor drug regimen compliance and illegal counterfeiting. |
|
|
*B-SMART™ Antibiotic Susceptibility Test A platform IVD technology using a novel nucleic acid format to identify a bacterial pathogen and determine its antibiotic susceptibility pattern. Laboratory proof-of-principle is ongoing and funded by a grant. For more information, please see our B-Smart™ Backgrounder. |
Out-licensed Technologies
|
*PrimaTB STAT-PAK® Lateral-flow serological TB Test for Non-human Primates developed with SBIR grants. |
|
